Home The Word Brain My Amedeo FAQ Privacy About   

As of October 2023, Amedeo had
12,263 active subscribers

  Malignant Melanoma

  Free Subscription

Articles published in J Invest Dermatol

Retrieve available abstracts of 124 articles:
HTML format

Single Articles

    November 2023
  1. LEE KJ, Soyer HP, Stark MS
    The Skin Molecular Ecosystem Holds the Key to Nevogenesis and Melanomagenesis.
    J Invest Dermatol. 2023 Nov 1:S0022-202X(23)02918.
    PubMed     Abstract available

    September 2023
  2. HAN JH, Lee S, Ju HJ, Kim M, et al
    Automated Mass Screening for Comorbidities of Vitiligo Using the National Health Insurance Database.
    J Invest Dermatol. 2023;143:1717-1723.
    PubMed     Abstract available

    August 2023
  3. FERRER CC, Marguet T, Vanwonterghem L, Erbek S, et al
    Serum IGF1 is a prognostic marker for resistance to targeted therapies and a predictive marker for anti-IGF1R therapy in melanoma.
    J Invest Dermatol. 2023 Aug 12:S0022-202X(23)02499.

  4. VESELY MD, Kidacki M, Gaule P, Gupta S, et al
    Immune inhibitory molecule PD-1H (VISTA) colocalizes with CD11b myeloid cells in melanoma and is associated with poor outcomes.
    J Invest Dermatol. 2023 Aug 7:S0022-202X(23)02483.
    PubMed     Abstract available

  5. MEHTA PP, Sun M, Betz-Stablein B, Halpern A, et al
    Improving Artificial Intelligence-Based Diagnosis on Pediatric Skin Lesions.
    J Invest Dermatol. 2023;143:1423-1429.
    PubMed     Abstract available

    July 2023
  6. AHMED F, Lim R, Moseley I, Hoang M, et al
    Neighborhood-level Socioeconomic Predictors of Melanoma Thickness, Ulceration, and Metastasis at a Rhode Island Academic Center.
    J Invest Dermatol. 2023 Jul 3:S0022-202X(23)02403.

  7. PHUNG M, Muralidharan V, Rotemberg V, Novoa RA, et al
    Best Practices for Clinical Skin Image Acquisition in Translational Artificial Intelligence Research.
    J Invest Dermatol. 2023;143:1127-1132.
    PubMed     Abstract available

    May 2023
    Correspondence concerning PTPN11 mosaicism causes a spectrum of pigmentary and vascular neurocutaneous disorders and predisposes to melanoma.
    J Invest Dermatol. 2023 May 24:S0022-202X(23)02127.

  9. GUO Z, Liu Q, Lan S, Niu N, et al
    Clinicopathological Features and Prognosis of Melanoma in Northeast China: a region-based cohort study of 229 consecutive cases.
    J Invest Dermatol. 2023 May 17:S0022-202X(23)02069.
    PubMed     Abstract available

  10. FERGUSON J, Eleftheriadou V, Nesnas J
    J Invest Dermatol. 2023 May 3:S0022-202X(23)02047.
    PubMed     Abstract available

  11. KANG Y, Ji Z, Li H, Tsao H, et al
    Divergent BRAF Inhibitor Resistance Mechanisms Revealed through Epigenetic Mapping.
    J Invest Dermatol. 2023;143:842-853.
    PubMed     Abstract available

    April 2023
  12. AKTARY Z, Raymond JH, Pouteaux M, Delmas V, et al
    Derivation and Use of Cell Lines from Mouse Models of Melanoma.
    J Invest Dermatol. 2023;143:538-544.
    PubMed     Abstract available

    March 2023
  13. MAROCCHI F, Palluzzi F, Nicoli P, Melixetian M, et al
    Actionable genetic screens unveil targeting of AURKA, MEK and fatty acid metabolism as an alternative therapeutic approach for advanced melanoma.
    J Invest Dermatol. 2023 Mar 30:S0022-202X(23)01952.
    PubMed     Abstract available

  14. EDDY K, Gupta K, Pelletier JC, Isola AL, et al
    J Invest Dermatol. 2023 Mar 28:S0022-202X(23)01951.
    PubMed     Abstract available

  15. LEICHNER GS, Schweitzer I, Dror S, Levin L, et al
    Primary melanoma miRNAs trafficking induce lymphangiogenesis.
    J Invest Dermatol. 2023 Mar 17:S0022-202X(23)01836.
    PubMed     Abstract available

  16. CHAGANI S, De Macedo MP, Carapeto F, Wang F, et al
    J Invest Dermatol. 2023 Mar 3:S0022-202X(23)00164.
    PubMed     Abstract available

  17. ERIKSSON I, Vainikka L, Waster P, Ollinger K, et al
    Lysosomal function and intracellular position determine the malignant phenotype in malignant melanoma.
    J Invest Dermatol. 2023 Mar 3:S0022-202X(23)00171.
    PubMed     Abstract available

    February 2023
  18. JOHANSSON PA, Palmer JM, Hamilton HR, Whiteman DC, et al
    Germline Variants in Childhood Cutaneous Melanoma.
    J Invest Dermatol. 2023 Feb 28:S0022-202X(23)00155.

  19. WANG G, Zeng D, Sweren E, Miao Y, et al
    m6A RNA methylation correlates with immune microenvironment and immunotherapy response of melanoma.
    J Invest Dermatol. 2023 Feb 24:S0022-202X(23)00095.
    PubMed     Abstract available

  20. RIBERO S, Lambertini M, Ferracin M, Dika E, et al
    Non-Coding RNA Investigations in Cutaneous Melanoma: a Step forward in Discovering Novel Biomarkers.
    J Invest Dermatol. 2023 Feb 24:S0022-202X(23)00088.

  21. GARCIA-SILVA S, Vico-Alonso C, Meyer L, Enderle D, et al
    Improved sensitivity in BRAFV600E detection in combined tissue and extracellular vesicles-based liquid biopsy in melanoma.
    J Invest Dermatol. 2023 Feb 15:S0022-202X(23)00091.

  22. MING Z, Lim SY, Stewart A, Pedersen B, et al
    IFNgamma signaling sensitizes melanoma cells to BH3 Mimetics.
    J Invest Dermatol. 2023 Feb 1:S0022-202X(23)00072.
    PubMed     Abstract available

    January 2023
  23. WESTPHAL D, Meinhardt M, Grutzmann K, Schone L, et al
    Identification of epigenetically regulated genes distinguishing intracranial from extracranial melanoma metastases.
    J Invest Dermatol. 2023 Jan 27:S0022-202X(23)00030.
    PubMed     Abstract available

    December 2022
  24. POLUBOTHU S, Bender N, Muthiah S, Zecchin D, et al
    PTPN11 mosaicism causes a spectrum of pigmentary and vascular neurocutaneous disorders and predisposes to melanoma.
    J Invest Dermatol. 2022 Dec 22:S0022-202X(22)02891.
    PubMed     Abstract available

  25. GUPTA I, Shankrit S, Narta K, Ghazi M, et al
    Whole exome-sequencing of vitiligo lesions indicate lower burden of somatic variations: implications in risk for non-melanoma skin cancers.
    J Invest Dermatol. 2022 Dec 16:S0022-202X(22)02884.

    November 2022
  26. DONG B, Simonson L, Vold S, Oldham E, et al
    Frizzled 6 promotes melanoma cell invasion but not proliferation by regulating canonical Wnt signaling and EMT.
    J Invest Dermatol. 2022 Nov 8. pii: S0022-202X(22)02660.
    PubMed     Abstract available

  27. ABDELAZEEM B, Abbas KS, Shehata J, Alfaar AS, et al
    Increased Risk of Subsequent Skin Melanoma in Patients with Retinoblastoma: SEER-Based Results.
    J Invest Dermatol. 2022;142:3123-3125.

  28. HARMS PW, Chan MP, Bresler SC, Andea AA, et al
    Comment on "An Epidemiologic Analysis of Melanoma Overdiagnosis in the United States, 1975-2017".
    J Invest Dermatol. 2022;142:3120-3122.

    October 2022
  29. LUU YT, Luo Q, Horner MJ, Shiels M, et al
    Risk of nonkeratinocyte skin cancers in people living with HIV during the era of antiretroviral therapy.
    J Invest Dermatol. 2022 Oct 7. pii: S0022-202X(22)01942.
    PubMed     Abstract available

  30. DIVINCENZO MJ, Schwarz E, Ren C, Barricklow Z, et al
    Expression patterns of microRNAs and associated target genes in ulcerated primary cutaneous melanoma.
    J Invest Dermatol. 2022 Oct 3. pii: S0022-202X(22)02640.
    PubMed     Abstract available

    September 2022
  31. CHAKRABORTY A, Perez M, Carroll JD, Antonopoulos A, et al
    Hypoxia controls the glycome signature and galectin-8 - ligand axis to promote pro-tumorigenic properties of metastatic melanoma.
    J Invest Dermatol. 2022 Sep 26. pii: S0022-202X(22)01931.
    PubMed     Abstract available

  32. KREUGER IZM, Slieker RC, van Groningen T, van Doorn R, et al
    Therapeutic Strategies for Targeting CDKN2A Loss in Melanoma.
    J Invest Dermatol. 2022 Sep 16. pii: S0022-202X(22)01769.
    PubMed     Abstract available

  33. LASHERAS-OTERO I, Feliu I, Maillo A, Moreno H, et al
    The regulators of peroxisomal acyl-carnitine shuttle CROT and CRAT promote metastasis in melanoma.
    J Invest Dermatol. 2022 Sep 1. pii: S0022-202X(22)01890.
    PubMed     Abstract available

    August 2022
  34. JOUR G, Illa-Bochaca I, Ibrahim M, Donnelly D, et al
    Genomic and transcriptomic analyses of NF1-mutant melanoma identify potential targeted approach for treatment.
    J Invest Dermatol. 2022 Aug 18. pii: S0022-202X(22)01780.
    PubMed     Abstract available

    July 2022
  35. CHOUSAKOS E, Kose K, Kurtansky NR, Dusza SW, et al
    J Invest Dermatol. 2022 Jul 13. pii: S0022-202X(22)01663.
    PubMed     Abstract available

    June 2022
  36. WIGGINS JM, Ali S, Polsky D
    Cell-Free DNA in Dermatology Research.
    J Invest Dermatol. 2022;142:1523-1528.
    PubMed     Abstract available

    May 2022
  37. VERGANI E, Busico A, Dugo M, Devecchi A, et al
    Genetic layout of melanoma lesions associates to BRAF/MEK-targeted therapy resistance and to transcriptional profiles.
    J Invest Dermatol. 2022 May 25. pii: S0022-202X(22)00400.
    PubMed     Abstract available

  38. KAINULAINEN K, Takabe P, Heikkinen S, Aaltonen N, et al
    M1 macrophages induce pro-tumor inflammation in melanoma cells via TNFR-NF-kappaB signaling.
    J Invest Dermatol. 2022 May 14. pii: S0022-202X(22)00393.
    PubMed     Abstract available

    April 2022
  39. LIU Y, Chi W, Tao L, Wang G, et al
    Ablation of H(+)/glucose Exporter SLC45A2 Enhances Melanosomal Glycolysis to Inhibit Melanin Biosynthesis and Promote Melanoma Metastasis.
    J Invest Dermatol. 2022 Apr 22. pii: S0022-202X(22)00301.
    PubMed     Abstract available

  40. CHANG GA, Robinson E, Wiggins JM, Zhang Y, et al
    Associations between TERT promoter mutations and survival in superficial spreading and nodular melanomas in a large prospective patient cohort.
    J Invest Dermatol. 2022 Apr 22. pii: S0022-202X(22)00304.
    PubMed     Abstract available

  41. LEE KJ, Stark MS
    In Vivo Melanoma Cell Morphology and Tumor Aggressiveness: The Promise of Reflectance Confocal Microscopy in Reducing Unnecessary Excisions.
    J Invest Dermatol. 2022 Apr 2. pii: S0022-202X(22)00079.

    March 2022
  42. BRENNER E, Rocken M
    A Commotion in the Skin: Developing Melanoma Immunotherapies.
    J Invest Dermatol. 2022 Mar 23. pii: S0022-202X(22)00097.
    PubMed     Abstract available

  43. FRANTZ WT, Ceol CJ
    Research Techniques Made Simple: Zebrafish Models for Human Dermatologic Disease.
    J Invest Dermatol. 2022;142.
    PubMed     Abstract available

    February 2022
  44. KAMADA H, Yasuhira S, Shibazaki M, Amano H, et al
    DUSP4 inactivation leads to reduced ERK activity via the upregulation of DUSP6 in melanoma cells.
    J Invest Dermatol. 2022 Feb 18. pii: S0022-202X(22)00126.
    PubMed     Abstract available

  45. YEPES S, Tucker MA, Koka H, Xiao Y, et al
    Integrated Analysis of Co-expression and Exome Sequencing to Prioritize Susceptibility Genes for Familial Cutaneous Melanoma.
    J Invest Dermatol. 2022 Feb 15. pii: S0022-202X(22)00118.
    PubMed     Abstract available

  46. LAZAR I, Clement E, Carrie L, Esteve D, et al
    Adipocyte extracellular vesicles decrease p16(INK4A) in melanoma: an additional link between obesity and cancer.
    J Invest Dermatol. 2022 Feb 9. pii: S0022-202X(22)00099.
    PubMed     Abstract available

  47. WANG D, Fu Z, Gao L, Zeng J, et al
    Increased IRF9-STAT2 signaling leads to adaptive resistance toward targeted therapy in melanoma by restraining GSDME-dependent pyroptosis.
    J Invest Dermatol. 2022 Feb 8. pii: S0022-202X(22)00096.
    PubMed     Abstract available

  48. LI Y, Wu J, Tian Y, Zhu Q, et al
    Med1 downregulation contributes to TGF-beta-induced metastasis by inhibiting Smad2 ubiquitination degradation in cutaneous melanoma.
    J Invest Dermatol. 2022 Feb 4. pii: S0022-202X(22)00081.
    PubMed     Abstract available

  49. EMRAN AA, Fisher DE
    Dual Targeting with EZH2 Inhibitor and STING Agonist to Treat Melanoma.
    J Invest Dermatol. 2022 Feb 4. pii: S0022-202X(21)02378.
    PubMed     Abstract available

  50. AZIN M, Demehri S
    STK11 Loss: A Novel Mechanism for Melanoma Metastasis with Therapeutic Implications.
    J Invest Dermatol. 2022 Feb 4. pii: S0022-202X(21)02345.
    PubMed     Abstract available

  51. GUIDA S, Guida G, Goding CR
    MC1R Functions, Expression, and Implications for Targeted Therapy.
    J Invest Dermatol. 2022;142:293-302.
    PubMed     Abstract available

  52. XU G, Luo Y, Wu W, Liu X, et al
    The Evolution of Acquired Resistance to BRAF(V600E) kinase inhibitor Is Sustained by IGF1-Driven Tumor Vascular Remodeling.
    J Invest Dermatol. 2022;142:445-458.
    PubMed     Abstract available

    January 2022
  53. OLSEN CM, Whiteman DC
    Cutaneous Melanoma in White Americans: A Tale of Two Epidemics.
    J Invest Dermatol. 2022 Jan 30. pii: S0022-202X(22)00003.
    PubMed     Abstract available

  54. CHU YS, Lee S, Lee SG, Chung KY, et al
    Deep Learning Algorithms for Predicting Breslow Thickness from Dermoscopic Images of Acral Lentiginous Melanomas.
    J Invest Dermatol. 2022 Jan 12. pii: S0022-202X(22)00008.

  55. BUSTOS MA, Hoon DSB
    Prognostic Utility of CpG Island Hypermethylated Phenotype in Early-Stage Invasive Primary Melanomas.
    J Invest Dermatol. 2022 Jan 11. pii: S0022-202X(21)02629.
    PubMed     Abstract available

  56. MARCONI A, Quadri M, Farnetani F, Ciardo S, et al
    In Vivo Melanoma Cell Morphology Reflects Molecular Signature and Tumor Aggressiveness.
    J Invest Dermatol. 2022 Jan 7. pii: S0022-202X(21)02683.
    PubMed     Abstract available

  57. BECHMANN N, Calsina B, Richter S, Pietzsch J, et al
    Therapeutic Potential of Nitric Oxide releasing Selective Estrogen Receptor Modulators (NO-SERMs) in Malignant Melanoma.
    J Invest Dermatol. 2022 Jan 3. pii: S0022-202X(21)02691.
    PubMed     Abstract available

    December 2021
  58. KUMPER M, Hessenthaler S, Zamek J, Niland S, et al
    J Invest Dermatol. 2021 Dec 27. pii: S0022-202X(21)02633.
    PubMed     Abstract available

  59. FANE ME, Chhabra Y, Spoerri L, Simmons JL, et al
    Reciprocal regulation of BRN2 and NOTCH1/2 signaling synergistically drives melanoma cell migration and invasion.
    J Invest Dermatol. 2021 Dec 24. pii: S0022-202X(21)02630.
    PubMed     Abstract available

  60. WANG Y, Ramachandran V, Sui D, Xu K, et al
    Evaluation of Plasma Interleukin-6 in Melanoma Patients as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker.
    J Invest Dermatol. 2021 Dec 21. pii: S0022-202X(21)02627.

  61. MUKHERJEE N, Dart CR, Amato CM, Honig-Frand A, et al
    Expression differences in BCL2 family members between uveal and cutaneous melanomas account for varying sensitivity to BH3 mimetics.
    J Invest Dermatol. 2021 Dec 20. pii: S0022-202X(21)02617.
    PubMed     Abstract available

  62. KURTANSKY NR, Dusza SW, Halpern AC, Hartman RI, et al
    An Epidemiologic Analysis of Melanoma Overdiagnosis in the United States, 1975-2017.
    J Invest Dermatol. 2021 Dec 10. pii: S0022-202X(21)02610.
    PubMed     Abstract available

  63. HRISTOVA DM, Fukumoto T, Takemori C, Gao L, et al
    J Invest Dermatol. 2021 Dec 6. pii: S0022-202X(21)02600.
    PubMed     Abstract available

  64. CHHABRA G, Ahmad N
    BRAF Inhibitors in Melanoma Management: When Friends Become Foes.
    J Invest Dermatol. 2021 Dec 3. pii: S0022-202X(21)02485.
    PubMed     Abstract available

    November 2021
  65. CONWAY K, Tsai YS, Edmiston SN, Parker JS, et al
    Characterization of the CpG island hypermethylated phenotype (CIMP) subclass in primary melanomas.
    J Invest Dermatol. 2021 Nov 26. pii: S0022-202X(21)02531.
    PubMed     Abstract available

  66. MA B, Anandasabapathy N
    Immune Checkpoint Blockade and Skin Toxicity Pathogenesis.
    J Invest Dermatol. 2021 Nov 26. pii: S0022-202X(21)02308.
    PubMed     Abstract available

  67. LIYANAGE U, MacGregor S, Bishop DT, Shi J, et al
    Multi-trait genetic analysis identifies auto-immune loci associated with cutaneous melanoma.
    J Invest Dermatol. 2021 Nov 20. pii: S0022-202X(21)02513.
    PubMed     Abstract available

  68. DEL ROSSO M, Fibbi G, Laurenzana A, Margheri F, et al
    A Possible Role for PAI-1 Blockade in Melanoma Immunotherapy.
    J Invest Dermatol. 2021;141:2566-2568.
    PubMed     Abstract available

    October 2021
  69. DZUNG A, Saltari A, Tiso N, Lyck R, et al
    STK11 Prevents Invasion Through STAT3/5 and FAK Repression in Cutaneous Melanoma.
    J Invest Dermatol. 2021 Oct 29. pii: S0022-202X(21)02466.
    PubMed     Abstract available

  70. KIM RH, Nomikou S, Coudray N, Jour G, et al
    Deep learning and pathomics analyses reveal cell nuclei as important features for mutation prediction of BRAF-mutated melanomas.
    J Invest Dermatol. 2021 Oct 29. pii: S0022-202X(21)02405.
    PubMed     Abstract available

  71. KIURU M, Kriner MA, Wong S, Zhu G, et al
    High-plex spatial RNA profiling reveals cell type-specific biomarker expression during melanoma development.
    J Invest Dermatol. 2021 Oct 23. pii: S0022-202X(21)02370.
    PubMed     Abstract available

  72. AHMED F, Tseng HY, Ahn A, Gunatilake D, et al
    Repurposing melanoma chemotherapy to activate inflammasomes in treatment of BRAF/MAPK inhibitor resistant melanoma.
    J Invest Dermatol. 2021 Oct 22. pii: S0022-202X(21)02384.
    PubMed     Abstract available

  73. AL RAHMOUN M, Ghiasvand R, Cairat M, Mahamat-Saleh Y, et al
    Statin Use and Skin Cancer Risk: A Prospective Cohort Study.
    J Invest Dermatol. 2021 Oct 22. pii: S0022-202X(21)02382.
    PubMed     Abstract available

  74. NJAUW CN, Ji Z, Pham DM, Simoneau A, et al
    Oncogenic KIT Induces Replication stress and Confers Cell Cycle Checkpoint Vulnerability in Melanoma.
    J Invest Dermatol. 2021 Oct 20. pii: S0022-202X(21)02347.
    PubMed     Abstract available

  75. JANDOVA J, Wondrak GT
    Vemurafenib drives EMT gene expression in BRAFi-resistant BRAF(V600E)/NRAS(Q61K) melanoma enhancing tumor growth and metastasis in a bioluminescent murine model.
    J Invest Dermatol. 2021 Oct 20. pii: S0022-202X(21)02368.
    PubMed     Abstract available

  76. NAGORE E, Viros A, Kumar R
    Positive Attributes of Anti-TERT CD4 T-Helper Type 1 Immune Responses in Melanoma.
    J Invest Dermatol. 2021 Oct 16. pii: S0022-202X(21)02269.
    PubMed     Abstract available

  77. CHILIBROSTE S, Monaco A, Plata MC, Vola M, et al
    Preclinical evaluation of LVR01 attenuated Salmonella as neoadjuvant intralesional therapy in combination with chemotherapy for melanoma treatment.
    J Invest Dermatol. 2021 Oct 15. pii: S0022-202X(21)02317.
    PubMed     Abstract available

    September 2021
  78. CHHABRA G, Singh CK, Guzman-Perez G, Ndiaye MA, et al
    Anti-melanoma effects of concomitant inhibition of SIRT1 and SIRT3 in Braf(V600E)/Pten(NULL) mice.
    J Invest Dermatol. 2021 Sep 28. pii: S0022-202X(21)02223.
    PubMed     Abstract available

  79. XU T, Dai J, Tang L, Yang L, et al
    EZH2 inhibitor enhances the STING agonist-induced antitumor immunity in melanoma.
    J Invest Dermatol. 2021 Sep 24. pii: S0022-202X(21)02227.
    PubMed     Abstract available

  80. EMMONS MF, Smalley KSM
    Ironing-Out the Details: New Strategies for Combining Ferroptosis Inhibitors with Immunotherapy in Melanoma.
    J Invest Dermatol. 2021 Sep 23. pii: S0022-202X(21)01436.
    PubMed     Abstract available

  81. ADELMANN CH, Rachmin I, Fisher DE
    MFN2 Stabilization: A Bridge for Endoplasmic Reticulum Stress Sensitivity in Melanoma.
    J Invest Dermatol. 2021 Sep 23. pii: S0022-202X(21)01224.
    PubMed     Abstract available

  82. GUTIERREZ-SEIJO A, Garcia-Martinez E, Barrio-Alonso C, Parra-Blanco V, et al
    Activin A sustains the metastatic phenotype of tumor associated macrophages and is a prognostic marker in human cutaneous melanoma.
    J Invest Dermatol. 2021 Sep 6. pii: S0022-202X(21)02171.
    PubMed     Abstract available

    August 2021
  83. DAS I, Tuominen R, Helleday T, Hansson J, et al
    Co-expression of MTH1 and PMS2 is associated with advanced disease and disease progression after therapy in melanoma.
    J Invest Dermatol. 2021 Aug 18. pii: S0022-202X(21)01689.

  84. NARDIN C, Laheurte C, Puzenat E, Boullerot L, et al
    Naturally occurring Telomerase-specific CD4 T cell Immunity in Melanoma.
    J Invest Dermatol. 2021 Aug 2. pii: S0022-202X(21)01667.
    PubMed     Abstract available

    July 2021
  85. MONTAUDIE H, Sormani L, Dadone-Montaudie B, Heim M, et al
    CLEC12B decreases melanoma proliferation by repressing STAT3.
    J Invest Dermatol. 2021 Jul 23. pii: S0022-202X(21)01464.
    PubMed     Abstract available

  86. QUADRI M, Comitato A, Palazzo E, Tiso N, et al
    Activation of PKG restricts melanoma growth and invasion by interfering with the EGF/EGFR pathway.
    J Invest Dermatol. 2021 Jul 12. pii: S0022-202X(21)01420.
    PubMed     Abstract available

  87. WANG S, Yi X, Wu Z, Guo S, et al
    CAMKK2 defines ferroptosis sensitivity of melanoma cells by regulating AMPK-Nrf2 pathway.
    J Invest Dermatol. 2021 Jul 6. pii: S0022-202X(21)01416.
    PubMed     Abstract available

  88. PATMANATHAN SN, Tong BT, Jackie Teo JH, Jonathan Ting YZ, et al
    A PDZ Protein GIPC3 Positively Modulates Hedgehog Signaling and Melanoma Growth.
    J Invest Dermatol. 2021 Jul 2. pii: S0022-202X(21)01414.
    PubMed     Abstract available

  89. CHU EY, Takeshita J, Ming ME
    Shedding Light on Disparities in Melanoma Care.
    J Invest Dermatol. 2021;141:1625-1626.
    PubMed     Abstract available

    June 2021
  90. SHEINBOIM D, Parikh S, Parikh R, Menuchin A, et al
    Slow transcription of the 99a/let-7c/125b-2 cluster results in differential miRNA expression and promotes melanoma phenotypic plasticity.
    J Invest Dermatol. 2021 Jun 26. pii: S0022-202X(21)01406.
    PubMed     Abstract available

  91. KLEINERMAN RA, Schonfeld SJ, Abramson DH, Francis JH, et al
    Increased risk of skin cancer in 1851 long-term retinoblastoma survivors.
    J Invest Dermatol. 2021 Jun 18. pii: S0022-202X(21)01334.
    PubMed     Abstract available

    May 2021
  92. WANG H, Yi X, Guo S, Wang S, et al
    The XBP1-MARCH5-MFN2 axis confers ER stress resistance by coordinating mitochondrial fission and mitophagy in melanoma.
    J Invest Dermatol. 2021 May 25. pii: S0022-202X(21)01243.
    PubMed     Abstract available

  93. TSENG YJ, Lee CH, Chen WY, Yang JL, et al
    Inhibition of plasminogen activator inhibitor-1 blocks programmed death ligand 1 endocytosis and improves the response of melanoma cells to immune checkpoint blockade.
    J Invest Dermatol. 2021 May 14. pii: S0022-202X(21)01230.
    PubMed     Abstract available

  94. JI Z, Njauw CN, Guhan S, Kumar R, et al
    Loss of ACK1 Upregulates EGFR and Mediates Resistance to BRAF Inhibition.
    J Invest Dermatol. 2021;141:1317-1324.
    PubMed     Abstract available

    April 2021
  95. MUNIZ TP, Sorotsky H, Kanjanapan Y, Rose AAN, et al
    Genomic Landscape of Malignant Peripheral Nerve Sheath Tumor-like Melanoma.
    J Invest Dermatol. 2021 Apr 5. pii: S0022-202X(21)01132.
    PubMed     Abstract available

  96. DU-HARPUR X, Arthurs C, Ganier C, Woolf R, et al
    Clinically Relevant Vulnerabilities of Deep Machine Learning Systems for Skin Cancer Diagnosis.
    J Invest Dermatol. 2021;141:916-920.

    March 2021
  97. HARBERS FN, Thier B, Stupia S, Zhu S, et al
    Melanoma differentiation trajectories determine sensitivity towards pre-existing CD8(+) tumor-infiltrating lymphocytes.
    J Invest Dermatol. 2021 Mar 30. pii: S0022-202X(21)01124.
    PubMed     Abstract available

  98. AL EMRAN A, Tseng HY, Gunatilake D, Cook SJ, et al
    A combination of epigenetic BET and CDK9 inhibitors for treatment of human melanoma.
    J Invest Dermatol. 2021 Mar 26. pii: S0022-202X(21)01121.
    PubMed     Abstract available

  99. GUHAN SM, Shaughnessy M, Rajadurai A, Taylor M, et al
    The molecular context of vulnerability for CDK9 suppression in triple wild-type melanoma.
    J Invest Dermatol. 2021 Mar 18. pii: S0022-202X(21)00977.
    PubMed     Abstract available

  100. PERES J, Damerell V, Chauhan J, Popovic A, et al
    TBX3 promotes melanoma migration by transcriptional activation of ID1 which prevents activation of E-cadherin by MITF.
    J Invest Dermatol. 2021 Mar 17. pii: S0022-202X(21)01001.
    PubMed     Abstract available

  101. MARCHETTI MA, Nanda JK, Mancebo SE, Dusza SW, et al
    Real-world application of a non-invasive 2-gene expression test for melanoma diagnosis.
    J Invest Dermatol. 2021 Mar 17. pii: S0022-202X(21)01018.

  102. FREUND L, Kjaer SK, Guleria S, Albieri V, et al
    Use of fertility drugs and risk of malignant melanoma: results from a large Danish population-based cohort study.
    J Invest Dermatol. 2021 Mar 16. pii: S0022-202X(21)01022.
    PubMed     Abstract available

  103. TIKOO S, Jain R, Tomasetig F, On K, et al
    Amelanotic B16-F10 melanoma compatible with advanced 3-D imaging modalities.
    J Invest Dermatol. 2021 Mar 3. pii: S0022-202X(21)00156.

    February 2021
  104. GRAMANN AK, Frantz WT, Dresser K, Ferreira Gomes CB, et al
    BMP signaling promotes neural crest identity and accelerates melanoma onset.
    J Invest Dermatol. 2021 Feb 18. pii: S0022-202X(21)00150.

  105. KIM KB, Soroceanu L, de Semir D, Millis SZ, et al
    Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach.
    J Invest Dermatol. 2021 Feb 18. pii: S0022-202X(21)00155.
    PubMed     Abstract available

  106. KOIKOV L, Starner RJ, Swope VB, Upadhyay P, et al
    Development of hMC1R Selective Small Agonists for Sunless Tanning and Prevention of Genotoxicity of UV in Melanocytes.
    J Invest Dermatol. 2021 Feb 17. pii: S0022-202X(21)00117.
    PubMed     Abstract available

  107. SCHEEREN FA, van Doorn R
    Inhibition of the Epigenetic Reader BRD4 Reduces SIRPalpha-Mediated Phagocytosis and Melanoma Invasion.
    J Invest Dermatol. 2021;141:252-254.
    PubMed     Abstract available

  108. OSTROWSKI SM, Fisher DE
    The Melanocyte Lineage Factor miR-211 Promotes BRAF(V600E) Inhibitor Resistance.
    J Invest Dermatol. 2021;141:250-252.
    PubMed     Abstract available

    January 2021
  109. SHAH P, Shao Y, Geller AC, Polsky D, et al
    Late stage melanoma in New York State: associations with socioeconomic factors and healthcare access at the county level.
    J Invest Dermatol. 2021 Jan 28. pii: S0022-202X(21)00031.
    PubMed     Abstract available

  110. YU WY, Hill ST, Chan ER, Pink JJ, et al
    Computational drug repositioning identifies statins as a modifier of prognostic genetic expression signatures and metastatic behavior in melanoma.
    J Invest Dermatol. 2021 Jan 5. pii: S0022-202X(20)32413.
    PubMed     Abstract available

  111. ZHOU Q, Kim SH, Perez-Lorenzo R, Liu C, et al
    Phenformin Promotes Keratinocyte Differentiation via the Calcineurin/NFAT Pathway.
    J Invest Dermatol. 2021;141:152-163.
    PubMed     Abstract available

    December 2020
  112. TRAVNICKOVA J, Patton EE
    Deciphering melanoma cell states and plasticity with zebrafish models.
    J Invest Dermatol. 2020 Dec 16. pii: S0022-202X(20)32400.
    PubMed     Abstract available

  113. FUKUMOTO T, Lin J, Fatkhutdinov N, Liu P, et al
    ARID2 deficiency correlates with the response to immune checkpoint blockade in melanoma.
    J Invest Dermatol. 2020 Dec 14. pii: S0022-202X(20)32396.
    PubMed     Abstract available

    November 2020
  114. DOEPNER M, Lee IY, Ridky TW
    Drug Resistant Melanoma May Be Vulnerable to Inhibitors of Serine Synthesis.
    J Invest Dermatol. 2020;140:2114-2116.
    PubMed     Abstract available

    October 2020
  115. POIZEAU F, Kerbrat S, Happe A, Rault C, et al
    Patients with metastatic melanoma receiving anticancer drugs: changes in overall survival, 2010-2017.
    J Invest Dermatol. 2020 Oct 10. pii: S0022-202X(20)32138.
    PubMed     Abstract available

    September 2020
  116. HUANG SW, Wang ST, Chang SH, Chuang KC, et al
    Imiquimod Exerts Antitumor Effects by Inducing Immunogenic Cell Death and Is Enhanced by the Glycolytic Inhibitor 2-Deoxyglucose.
    J Invest Dermatol. 2020;140:1771-1783.
    PubMed     Abstract available

    August 2020
  117. RODGERS CB, Broit N, Johansson PA, Pritchard AL, et al
    Attack of the Subclones: Accurate Detection of Mutational Heterogeneity in Bulk DNA from Tumors.
    J Invest Dermatol. 2020;140:1501-1503.
    PubMed     Abstract available

  118. QUAN VL, Zhang B, Zhang Y, Mohan LS, et al
    Integrating Next-Generation Sequencing with Morphology Improves Prognostic and Biologic Classification of Spitz Neoplasms.
    J Invest Dermatol. 2020;140:1599-1608.
    PubMed     Abstract available

    July 2020
  119. TETZLAFF MT, Farah M
    Without Missing a Beat: Absence of Cilia Informs the Diagnosis of Histopathologically Challenging Spitzoid Melanocytic Neoplasms.
    J Invest Dermatol. 2020;140:1320-1323.
    PubMed     Abstract available

    June 2020
  120. RAHMAN H, Kumar D, Liu T, Okwundu N, et al
    Aspirin protects melanocytes and keratinocytes against UVB-induced DNA damage in vivo.
    J Invest Dermatol. 2020 Jun 19. pii: S0022-202X(20)31684.
    PubMed     Abstract available

    April 2020
  121. HALSE H, Caramia F, McLean CA, Wang M, et al
    A Distinct Pretreatment Immune Gene Signature in Lentigo Maligna Is Associated with Imiquimod Response.
    J Invest Dermatol. 2020;140:869-877.
    PubMed     Abstract available

    March 2020
  122. KIM E, Panzella L, Napolitano A, Payne GF, et al
    Redox Activities of Melanins Investigated by Electrochemical Reverse Engineering: Implications for their Roles in Oxidative Stress.
    J Invest Dermatol. 2020;140:537-543.
    PubMed     Abstract available

    January 2020
  123. LANG UE, Torres R, Cheung C, Vladar EK, et al
    Ciliation index is a useful diagnostic tool in challenging spitzoid melanocytic neoplasms.
    J Invest Dermatol. 2020 Jan 21. pii: S0022-202X(20)30038.
    PubMed     Abstract available

    December 2019
  124. CHITSAZAN A, Lambie D, Ferguson B, Handoko HY, et al
    Unexpected High Levels of BRN2/POU3F2 Expression in Human Dermal Melanocytic Nevi.
    J Invest Dermatol. 2019 Dec 24. pii: S0022-202X(19)33492.

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.